{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:07:11Z","timestamp":1768716431623,"version":"3.49.0"},"reference-count":93,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"<jats:p>Enteric fever is caused by the infection of Gram-negative bacteria, <jats:italic>Salmonella enterica<\/jats:italic> serovar Typhi and <jats:italic>Salmonella enterica<\/jats:italic> serovar Paratyphi (<jats:italic>S.<\/jats:italic> Paratyphi) A, B and C, through contaminated food and water. The disease almost exclusively affects the populations living in low- and middle-income countries, with the World Health Organization Southeast Asian Region (WHO SEAR) having the highest endemicity. Despite humans being the sole reservoir of infection and antibiotics and vaccines are made available, the disease was not taken up for elimination until recently due to several biological and technical reasons, including the lack of accurate and region-specific disease surveillance data in the real-time diagnostic inaccuracy of acute infections, difficulty in identifying the chronic asymptomatic carriers who are the major reservoirs of infection and the absence of a political will. However, there is now a renewed interest and effort to control the disease in the endemic areas with the help of better surveillance tools to monitor disease burden, wider availability of more accurate blood culture methods for diagnosis, and above all, cost-effective typhoid conjugate vaccines (TCVs) that can provide a high level of durable protection, particularly against the multidrug-resistant strains and to the age group most commonly affected by the disease. However, despite the commercial availability of a few TCVs, they are still in the development stage. Several questions need to be answered before they are taken up for routine immunization in countries like India. Furthermore, typhoid vaccines with a wider coverage, including additional efficacy against <jats:italic>Salmonella Paratyphi<\/jats:italic> A and B and preferably the non-typhoidal <jats:italic>Salmonella<\/jats:italic> (NTS) serovars, for which no vaccines are currently available would be more desirable. We have developed several subunit vaccine candidates containing the glycoconjugates of the surface polysaccharides of typhoidal and non-typhoidal <jats:italic>Salmonellae<\/jats:italic> and an intrinsic <jats:italic>Salmonella<\/jats:italic> protein that functions as both antigen and adjuvant. We also developed a novel mouse model of oral <jats:italic>Salmonella<\/jats:italic> Typhi infection to test the candidate vaccines, which demonstrated broad protective efficacy against <jats:italic>Salmonella spp<\/jats:italic>. through the induction of humoral and cell-mediated immunity as well as memory response.<\/jats:p>","DOI":"10.25259\/ijmr_1382_2024","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T07:34:15Z","timestamp":1732779255000},"page":"379-390","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Typhoid &amp; paratyphoid vaccine development in the laboratory: a review &amp; in-country experience"],"prefix":"10.25259","volume":"160","author":[{"given":"Suparna","family":"Chakraborty","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, ICMR National Institute for Research in Bacterial Infection, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santasabuj","family":"Das","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Occupational Health, Ahmedabad, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"10.25259\/IJMR_1382_2024\/ref-1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.15585\/mmwr.mm7207a2","article-title":"Typhoid fever surveillance, incidence estimates, and progress toward typhoid conjugate vaccine introduction - Worldwide, 2018-2022","volume":"72","author":"Hancuh","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.25259\/IJMR_1382_2024\/ref-2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","article-title":"The global burden of typhoid and paratyphoid fevers: a systematic analysis for the global burden of disease study 2017","volume":"19","author":"Typhoid","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-3","doi-asserted-by":"crossref","first-page":"e0005376","DOI":"10.1371\/journal.pntd.0005376","article-title":"The burden of typhoid fever in low- and middle-income countries: A meta-regression approach","volume":"11","author":"Antill\u00f3n","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-4","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1093\/cid\/ciy1094","article-title":"Global typhoid fever incidence: A systematic review and meta-analysis","volume":"68","author":"Marchello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-5","doi-asserted-by":"crossref","first-page":"S499","DOI":"10.1093\/cid\/ciz705","article-title":"Spatial and temporal patterns of typhoid and paratyphoid fever outbreaks: A worldwide review, 1990-2018","volume":"69","author":"Kim","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-6","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2209449","article-title":"Burden of typhoid and paratyphoid fever in India","volume":"388","author":"John","year":"2023","journal-title":"N Engl J Med"},{"key":"10.25259\/IJMR_1382_2024\/ref-7","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/infdis\/jiab187","article-title":"Geographic pattern of typhoid fever in India: A model-based estimate of cohort and surveillance data","volume":"224","author":"Cao","year":"2021","journal-title":"J Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-8","doi-asserted-by":"crossref","first-page":"e0004616","DOI":"10.1371\/journal.pntd.0004616","article-title":"The burden of typhoid and paratyphoid in India: Systematic review and meta-analysis","volume":"10","author":"John","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0140-6736(98)09001-1","article-title":"Typhoid fever in children aged less than 5 years","volume":"354","author":"Sinha","year":"1999","journal-title":"Lancet"},{"key":"10.25259\/IJMR_1382_2024\/ref-10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0035-9203(66)90310-5","article-title":"Salmonella paratyphi A infection in India: Incidence and phage types","volume":"60","author":"Saxena","year":"1966","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.25259\/IJMR_1382_2024\/ref-11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/0255-0857.58730","article-title":"Emerging salmonella paratyphi A enteric fever and changing trends in antimicrobial resistance pattern of Salmonella in Shimla","volume":"28","author":"Verma","year":"2010","journal-title":"Indian J Med Microbiol"},{"key":"10.25259\/IJMR_1382_2024\/ref-12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/09603120601093188","article-title":"Increasing prevalence of Salmonella enterica serotype Paratyphi-A in patients with enteric fever in a periurban slum setting of Kolkata, India","volume":"16","author":"Palit","year":"2006","journal-title":"Int J Environ Health Res"},{"key":"10.25259\/IJMR_1382_2024\/ref-13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0255-0857(21)02838-3","article-title":"Enteric fever due to S. paratyphia - an emerging problem","volume":"22","author":"Mendiratta","year":"2004","journal-title":"Indian J Med Microbiol"},{"key":"10.25259\/IJMR_1382_2024\/ref-14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1017\/S0950268805005844","article-title":"Antibiogram pattern and seasonality of Salmonella serotypes in a North Indian tertiary care hospital","volume":"134","author":"Mohanty","year":"2006","journal-title":"Epidemiol Infect"},{"key":"10.25259\/IJMR_1382_2024\/ref-15","first-page":"95","article-title":"An increase in enteric fever cases due to Salmonella Paratyphi A in & around Chandigarh","volume":"129","author":"Gupta","year":"2009","journal-title":"Indian J Med Res"},{"key":"10.25259\/IJMR_1382_2024\/ref-16","first-page":"CD010452","article-title":"Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins","volume":"11","author":"Kuehn","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.25259\/IJMR_1382_2024\/ref-17","doi-asserted-by":"crossref","first-page":"e0305692","DOI":"10.1371\/journal.pone.0305692","article-title":"The cost of typhoid illness in low- and middle-income countries, a scoping review of the literature","volume":"19","author":"Debellut","year":"2024","journal-title":"PLoS One"},{"key":"10.25259\/IJMR_1382_2024\/ref-18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-3156.2010.02711.x","article-title":"Cost of illness due to typhoid fever in five Asian countries","volume":"16","author":"Poulos","year":"2011","journal-title":"Trop Med Int Health"},{"key":"10.25259\/IJMR_1382_2024\/ref-19","first-page":"304","article-title":"Costs of illness due to typhoid fever in an Indian urban slum community: Implications for vaccination policy","volume":"22","author":"Bahl","year":"2004","journal-title":"J Health Popul Nutr"},{"key":"10.25259\/IJMR_1382_2024\/ref-20","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1093\/cid\/ciy1122","article-title":"A Review of the economic evidence of typhoid fever and typhoid vaccines","volume":"68","author":"Luthra","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-21","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1016\/j.vaccine.2021.06.003","article-title":"Cost effectiveness of typhoid vaccination in India","volume":"39","author":"Chauhan","year":"2021","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4103\/ijmr.IJMR_411_18","article-title":"Typhoid fever: Control & challenges in India","volume":"150","author":"Mukhopadhyay","year":"2019","journal-title":"Indian J Med Res"},{"key":"10.25259\/IJMR_1382_2024\/ref-23","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1093\/cid\/ciaa1323","article-title":"Antimicrobial resistance in typhoidal Salmonella: Surveillance for enteric fever in Asia project, 2016-2019","volume":"71","author":"Qamar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-24","doi-asserted-by":"crossref","first-page":"794868","DOI":"10.3389\/fpubh.2021.794868","article-title":"Rising XDR-Typhoid fever cases in Pakistan: Are we heading back to the pre-antibiotic era?","volume":"9","author":"Butt","year":"2022","journal-title":"Front Public Health"},{"key":"10.25259\/IJMR_1382_2024\/ref-25","doi-asserted-by":"crossref","first-page":"e0011723","DOI":"10.1371\/journal.pntd.0011723","article-title":"Trends in antimicrobial resistance amongst Salmonella Paratyphi A isolates in Bangladesh: 1999-2021","volume":"17","author":"Sajib","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-26","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/ciaa585","article-title":"Assessing the feasibility of typhoid elimination","volume":"71","author":"Stanaway","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-27","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1016\/S2214-109X(21)00255-2","article-title":"Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: A cohort study","volume":"9","author":"Yousafzai","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.25259\/IJMR_1382_2024\/ref-28","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1093\/ofid\/ofad055","article-title":"Taking on Typhoid: Eliminating typhoid fever as a global health problem","volume":"10","author":"Chen","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-29","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.vaccine.2021.03.017","article-title":"Richard Pfeiffer's typhoid vaccine and Almroth Wright's claim to priority","volume":"39","author":"Williamson","year":"2021","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-30","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1093\/cid\/ciaa504","article-title":"Review on the recent advances on typhoid vaccine development and challenges ahead","volume":"71","author":"Syed","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-31","doi-asserted-by":"crossref","first-page":"C55","DOI":"10.1016\/j.vaccine.2015.04.028","article-title":"Typhoid fever vaccination strategies","volume":"33","author":"Date","year":"2015","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-32","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1128\/IAI.68.3.1196-1201.2000","article-title":"Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers","volume":"68","author":"Tacket","year":"2000","journal-title":"Infect Immun"},{"key":"10.25259\/IJMR_1382_2024\/ref-33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clim.2010.11.006","article-title":"Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans","volume":"138","author":"Wahid","year":"2011","journal-title":"Clin Immunol"},{"key":"10.25259\/IJMR_1382_2024\/ref-34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, March 2018 - Recommendations","volume":"37","author":"World Health Organization","year":"2019","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-35","doi-asserted-by":"crossref","first-page":"e1561","DOI":"10.1016\/S2214-109X(21)00346-6","article-title":"Efficacy of typhoid conjugate vaccine in Nepal: Final results of a phase 3, randomized, controlled trial","volume":"9","author":"Shakya","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.25259\/IJMR_1382_2024\/ref-36","doi-asserted-by":"crossref","first-page":"101925","DOI":"10.1016\/j.eclinm.2023.101925","article-title":"Assessment of vaccine herd protection in a cluster-randomized trial of Vi conjugate vaccine against typhoid fever: Results of further analysis","volume":"58","author":"Khanam","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.25259\/IJMR_1382_2024\/ref-37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(23)02031-7","article-title":"Efficacy of typhoid conjugate vaccine: Final analysis of a 4-year, phase 3, randomized controlled trial in Malawian children","volume":"403","author":"Patel","year":"2024","journal-title":"Lancet"},{"key":"10.25259\/IJMR_1382_2024\/ref-38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.4161\/hv.19158","article-title":"Glycoconjugate vaccine strategies for protection against invasive Salmonella infections","volume":"8","author":"Simon","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.25259\/IJMR_1382_2024\/ref-39","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/CVI.00532-10","article-title":"The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines","volume":"18","author":"Thiem","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.25259\/IJMR_1382_2024\/ref-40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: Results from two randomized, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-41","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/S2214-109X(24)00055-X","article-title":"Typhoid conjugate vaccines: a step towards typhoid control","volume":"12","author":"Shakya","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.25259\/IJMR_1382_2024\/ref-42","doi-asserted-by":"crossref","first-page":"2043103","DOI":"10.1080\/21645515.2022.2043103","article-title":"A multicenter, single-blind, randomized, phase-2\/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM(197) conjugate typhoid vaccine (TyphiBEV(TM)) in healthy infants, children, and adults in comparison with a licensed comparator","volume":"18","author":"ThuluvaS","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.25259\/IJMR_1382_2024\/ref-43","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.vaccine.2022.12.007","article-title":"A phase ii\/iii, multicenter, observer-blinded, randomized, non-inferiority and safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV\u00ae in healthy 6 months-45 years aged participants","volume":"41","author":"Ok Baik","year":"2023","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-44","doi-asserted-by":"crossref","first-page":"e0211784","DOI":"10.1371\/journal.pone.0211784","article-title":"Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine","volume":"14","author":"Medise","year":"2019","journal-title":"PLoS One"},{"key":"10.25259\/IJMR_1382_2024\/ref-45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1473-3099(21)00455-2","article-title":"Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: An observer-blind, active-controlled, randomized, non-inferiority, phase 3 trial","volume":"22","author":"Kumar Rai","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41541-022-00434-8","article-title":"Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose","volume":"7","author":"Capeding","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.25259\/IJMR_1382_2024\/ref-47","first-page":"CD001261","article-title":"Vaccines for preventing typhoid fever","volume":"5","author":"Milligan","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.25259\/IJMR_1382_2024\/ref-48","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0264-410X(99)00231-5","article-title":"Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine","volume":"17","author":"Levine","year":"1999","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-49","doi-asserted-by":"crossref","first-page":"S770","DOI":"10.1093\/infdis\/jiab393","article-title":"Prospects of future typhoid and paratyphoid vaccines in endemic countries","volume":"224","author":"Shakya","year":"2021","journal-title":"J Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-50","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/ofid\/ofad041","article-title":"Salmonella combination vaccines: Moving beyond typhoid","volume":"10","author":"MacLennan","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0264-410X(92)90392-W","article-title":"Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain","volume":"10","author":"Tacket","year":"1992","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1086\/421469","article-title":"Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide","volume":"190","author":"Tacket","year":"2004","journal-title":"J Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-53","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/173.6.1408","article-title":"phoP\/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers","volume":"173","author":"Hohmann","year":"1996","journal-title":"J Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-54","doi-asserted-by":"crossref","first-page":"e11778","DOI":"10.1371\/journal.pone.0011778","article-title":"A randomized trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children","volume":"5","author":"Tran","year":"2010","journal-title":"PLoS One"},{"key":"10.25259\/IJMR_1382_2024\/ref-55","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1016\/j.vaccine.2010.03.019","article-title":"Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar Paratyphi A enteric fever vaccine candidates","volume":"28","author":"Roland","year":"2010","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-56","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ijmm.2015.07.004","article-title":"Safety and immunogenicity of an attenuated Salmonella enterica serovar Paratyphi A vaccine candidate","volume":"305","author":"Xiong","year":"2015","journal-title":"Int J Med Microbiol"},{"key":"10.25259\/IJMR_1382_2024\/ref-57","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/1348-0421.12276","article-title":"Construction of an attenuated Salmonella enterica serovar Paratyphi A vaccine strain harboring defined mutations in htrA and yncD","volume":"59","author":"Zhu","year":"2015","journal-title":"Microbiol Immunol"},{"key":"10.25259\/IJMR_1382_2024\/ref-58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clim.2019.03.003","article-title":"Cell mediated immune responses elicited in volunteers following immunization with candidate live oral Salmonella enterica serovar Paratyphi A attenuated vaccine strain CVD 1902","volume":"201","author":"Wahid","year":"2019","journal-title":"Clin Immunol"},{"key":"10.25259\/IJMR_1382_2024\/ref-59","first-page":"78","article-title":"Screening of the Salmonella paratyphi A CMCC 50973 strain outer membrane proteins for the identification of potential vaccine targets","volume":"5","author":"Yang","year":"2012","journal-title":"Mol Med Rep"},{"key":"10.25259\/IJMR_1382_2024\/ref-60","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1128\/iai.64.7.2709-2715.1996","article-title":"Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls","volume":"64","author":"Konadu","year":"1996","journal-title":"Infect Immun"},{"key":"10.25259\/IJMR_1382_2024\/ref-61","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1128\/IAI.68.3.1529-1534.2000","article-title":"Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam","volume":"68","author":"Konadu","year":"2000","journal-title":"Infect Immun"},{"key":"10.25259\/IJMR_1382_2024\/ref-62","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.4161\/hv.28130","article-title":"Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid","volume":"10","author":"Ali","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.25259\/IJMR_1382_2024\/ref-63","doi-asserted-by":"crossref","first-page":"e47039","DOI":"10.1371\/journal.pone.0047039","article-title":"O:2-CRM(197) conjugates against Salmonella Paratyphi A","volume":"7","author":"Micoli","year":"2012","journal-title":"PLoS One"},{"key":"10.25259\/IJMR_1382_2024\/ref-64","doi-asserted-by":"crossref","first-page":"15953","DOI":"10.1002\/chem.202002401","article-title":"Syntheses of Salmonella Paratyphi A associated oligosaccharide antigens and development towards anti-paratyphoid fever vaccines","volume":"26","author":"Dhara","year":"2020","journal-title":"Chemistry"},{"key":"10.25259\/IJMR_1382_2024\/ref-65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/649541","article-title":"Global trends in typhoid and paratyphoid Fever","volume":"50","author":"Crump","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-66","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1086\/518141","article-title":"Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B","volume":"45","author":"Levine","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-67","doi-asserted-by":"crossref","first-page":"e0008783","DOI":"10.1371\/journal.pntd.0008783","article-title":"Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomized controlled human infection model","volume":"14","author":"Gibani","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-68","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.vaccine.2016.03.106","article-title":"Status of paratyphoid fever vaccine research and development","volume":"34","author":"Martin","year":"2016","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-69","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/vaccines11010091","article-title":"A Bivalent MAPS vaccine induces protective antibody responses against Salmonella Typhi and Paratyphi A","volume":"11","author":"Zhang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.25259\/IJMR_1382_2024\/ref-70","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jbiotec.2015.01.020","article-title":"Simplified low-cost production of O-antigen from Salmonella Typhimurium Generalized Modules for Membrane Antigens (GMMA)","volume":"198","author":"Meloni","year":"2015","journal-title":"J Biotechnol"},{"key":"10.25259\/IJMR_1382_2024\/ref-71","doi-asserted-by":"crossref","first-page":"e00699","DOI":"10.1128\/IAI.00699-20","article-title":"Salmonella paratyphia outer membrane vesicles displaying vi polysaccharide as a multivalent vaccine against enteric fever","volume":"89","author":"Gasperini","year":"2021","journal-title":"Infect Immun"},{"key":"10.25259\/IJMR_1382_2024\/ref-72","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.vaccine.2023.01.054","article-title":"Vaccine value profile for Salmonella enterica serovar Paratyphi A","volume":"41","author":"Martin","year":"2023","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-73","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/CVI.00058-12","article-title":"Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans","volume":"19","author":"Wahid","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.25259\/IJMR_1382_2024\/ref-74","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/sji.12151","article-title":"Cross-reactive immune response induced by the Vi capsular polysaccharide typhoid vaccine against Salmonella Paratyphi strains","volume":"79","author":"Pakkanen","year":"2014","journal-title":"Scand J Immunol"},{"key":"10.25259\/IJMR_1382_2024\/ref-75","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14760584.2017.1374861","article-title":"Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines","volume":"16","author":"Zuckerman","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.25259\/IJMR_1382_2024\/ref-76","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1073\/pnas.1016180108","article-title":"An adhesion protein of Salmonella enterica serovar Typhi is required for pathogenesis and potential target for vaccine development","volume":"108","author":"Ghosh","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.25259\/IJMR_1382_2024\/ref-77","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1128\/iai.38.3.948-952.1982","article-title":"Innate resistance of mice to Salmonella typhi infection","volume":"38","author":"O\u2019Brien","year":"1982","journal-title":"Infect Immun"},{"key":"10.25259\/IJMR_1382_2024\/ref-78","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1189\/jlb.1111554","article-title":"Slc11a1 (Nramp1) impairs growth of Salmonella enterica serovar typhimurium in macrophages via stimulation of lipocalin-2 expression","volume":"92","author":"Fritsche","year":"2012","journal-title":"J Leukoc Biol"},{"key":"10.25259\/IJMR_1382_2024\/ref-79","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/267063a0","article-title":"Effects of iron chelators and iron overload on Salmonella infection","volume":"267","author":"Jones","year":"1977","journal-title":"Nature"},{"key":"10.25259\/IJMR_1382_2024\/ref-80","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bbamcr.2016.12.002","article-title":"Iron mediated toxicity and programmed cell death: A review and a re-examination of existing paradigms","volume":"1864","author":"Eid","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.25259\/IJMR_1382_2024\/ref-81","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-024-00812-4","article-title":"Intranasal immunization of mice with chimera of Salmonella Typhi protein elicits protective intestinal immunity","volume":"9","author":"Chakraborty","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.25259\/IJMR_1382_2024\/ref-82","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1016\/j.vaccine.2017.07.035","article-title":"A recombinant protein of Salmonella Typhi induces humoral and cell-mediated immune responses including memory responses","volume":"35","author":"Das","year":"2017","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-83","doi-asserted-by":"crossref","first-page":"100540","DOI":"10.1016\/j.eclinm.2020.100540","article-title":"Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind study","volume":"27","author":"Capeding","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.25259\/IJMR_1382_2024\/ref-84","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1001\/jama.293.14.1751","article-title":"Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: A randomized controlled trial","volume":"293","author":"Buttery","year":"2005","journal-title":"JAMA"},{"key":"10.25259\/IJMR_1382_2024\/ref-85","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/01.inf.0000227725.61495.c4","article-title":"Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine co-administered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine","volume":"25","author":"Tejedor","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.25259\/IJMR_1382_2024\/ref-86","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax006","article-title":"Tetanus-diphtheria-pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (co-administered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial","volume":"24","author":"Tashani","year":"2017","journal-title":"J Travel Med"},{"key":"10.25259\/IJMR_1382_2024\/ref-87","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.vaccine.2014.11.026","article-title":"Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: Biophysical and immunochemical interpretation","volume":"33","author":"Pecetta","year":"2015","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-88","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1016\/j.vaccine.2010.02.103","article-title":"Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies","volume":"28","author":"Jegerlehner","year":"2010","journal-title":"Vaccine"},{"key":"10.25259\/IJMR_1382_2024\/ref-89","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3390\/toxins7030974","article-title":"Cholera toxin B: one subunit with many pharmaceutical applications","volume":"7","author":"Baldauf","year":"2015","journal-title":"Toxins (Basel)"},{"key":"10.25259\/IJMR_1382_2024\/ref-90","doi-asserted-by":"crossref","first-page":"1304170","DOI":"10.3389\/fimmu.2023.1304170","article-title":"A candidate glycoconjugate vaccine induces protective antibodies in the serum and intestinal secretions, antibody recall response and memory T cells and protects against both typhoidal and non-typhoidal Salmonella serovars","volume":"14","author":"Haldar","year":"2023","journal-title":"Front Immunol"},{"key":"10.25259\/IJMR_1382_2024\/ref-91","doi-asserted-by":"crossref","first-page":"e0006522","DOI":"10.1371\/journal.pntd.0006522","article-title":"Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult mice","volume":"12","author":"Baliban","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.25259\/IJMR_1382_2024\/ref-92","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.carres.2014.12.002","article-title":"Structural analysis of the O-acetylated O-polysaccharide isolated from Salmonella paratyphi A and used for vaccine preparation","volume":"404","author":"Ravenscroft","year":"2015","journal-title":"Carbohydr Res"},{"key":"10.25259\/IJMR_1382_2024\/ref-93","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2017.00168","article-title":"Immunogenicity of a bivalent adjuvanted glycoconjugate vaccine against Salmonella typhimurium and Salmonella enteritidis","volume":"8","author":"Fiorino","year":"2017","journal-title":"Front Immunol"}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/typhoid-paratyphoid-vaccine-development-in-the-laboratory-a-review-in-country-experience\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/typhoid-paratyphoid-vaccine-development-in-the-laboratory-a-review-in-country-experience\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T03:29:54Z","timestamp":1734665394000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/typhoid-paratyphoid-vaccine-development-in-the-laboratory-a-review-in-country-experience\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":93,"alternative-id":["10.25259\/IJMR_1382_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_1382_2024","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"article-number":"379"}}